頭頸癌治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032

2023年，全球頭頸癌治療市場價值為18億美元，預計2024年至2032年複合年成長率為8.9%。 GLOBOCAN 的統計數據強調頭頸癌是全球最常見的癌症之一。此外，菸草和酒精的消費量不斷增加，這兩種頭頸癌的重要風險因素，將進一步推動該產業的成長。

隨著個體年齡的成長，他們對基因突變的易感性會增加，而身體的 DNA 修復機制會減弱，從而增加癌症風險。這種自然老化軌跡表明，不斷擴大的老年人口可能會導致癌症病例激增。美國癌症協會指出，大約 57% 的新診斷癌症和 75% 的癌症相關死亡發生在 65 歲及以上的人群中。值得注意的是，這個年齡層是成長最快的部分，尤其是在美國等已開發國家

頭頸癌盛行率的上升極大地推動了市場的發展。例如，美國國家癌症研究所預計，到 2024 年，美國將有 71,000 人被診斷出患有咽、喉或口腔癌症。 HPV，尤其是第 16 型，對口咽癌，尤其是影響扁桃體和舌根的口咽癌構成顯著風險。 HPV 相關感染的增加與這些癌症的增加有關。

整個產業分為治療類型、給藥途徑、配銷通路和地區。

按治療類型細分的市場包括化療、免疫療法、標靶治療等。 2023年，免疫治療領域引領市場，佔9.727億美元。免疫療法成為頭頸癌患者的希望燈塔，尤其是那些處於晚期或復發階段的患者。透過利用人體的免疫系統來識別和對抗癌細胞，免疫療法為手術、放療和化療等傳統治療提供了一種引人注目的替代方案。

頭頸癌治療的給藥途徑包括注射、口服方法等。 2023 年，注射劑佔了 57.4% 的主導佔有率。這些藥物針對癌症或免疫細胞上的特定蛋白質，需要直接血流給藥以獲得最佳療效。

北美引領全球頭頸癌治療市場，2023 年收入為6.614 億美元，預計到2032 年將達到14 億美元。推出和實施。此外，患者意識的提高以及獲得尖端治療方案的機會鞏固了北美在行業格局中的地位。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 頭頸癌發生率增加
    • 老年人口基數不斷增加
    • 加大研發投入以開發新藥
    • 支持性報銷政策和疾病意識的提高
  • 產業陷阱與挑戰
    • 治療費用高
    • 副作用和安全問題
• 成長潛力分析
• 監管環境
• 管道分析
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按治療類型，2021 - 2032 年

• 主要趨勢
• 化療
• 免疫療法
• 標靶治療
• 其他療法

第 6 章：市場估計與預測：按管理途徑，2021 年至 2032 年

• 主要趨勢
• 可注射
• 口服
• 其他給藥途徑

第 7 章：市場估計與預測：按配銷通路，2021 - 2032 年

• 主要趨勢
• 醫院藥房
• 零售和專業藥房
• 網路藥房

第 8 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 9 章：公司簡介

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca plc
• Bristol-Myers Squibb Company (BMS)
• C.H. Boehringer Sohn AG and Co. KG
• Clinigen Group plc.
• Coherus BioSciences
• Cumberland Pharmaceuticals, Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• GSK plc
• Merck and Co., Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.

The Global Head and Neck Cancer Therapeutics Market was valued at USD 1.8 billion in 2023 and is projected to grow at a CAGR of 8.9% from 2024 to 2032. The primary driver of this market growth is the rising prevalence of head and neck cancer. Statistics from GLOBOCAN highlight head and neck cancer as one of the most prevalent cancers worldwide. Furthermore, the escalating consumption of tobacco and alcohol, both significant risk factors for head and neck cancers, is poised to further propel the industry growth.

As individuals age, their susceptibility to genetic mutations heightens, and the body's DNA repair mechanisms wane, amplifying cancer risks. This natural aging trajectory indicates that an expanding elderly demographic will likely see a surge in cancer cases. The American Cancer Society notes that approximately 57% of new cancer diagnoses and 75% of cancer-related deaths are in individuals aged 65 years and older. Notably, this age bracket is the fastest growing segment, especially in developed nations like the U.S.

The rising prevalence of head and neck cancer significantly propels the market. For instance, in 2024, the National Cancer Institute projects that 71,000 individuals in the U.S. will be diagnosed with cancers of the pharynx, larynx, or oral cavity. HPV, especially type 16, poses a notable risk for oropharyngeal cancers, particularly those impacting the tonsils and tongue's base. An uptick in HPV-related infections correlates with a rise in these cancers.

The overall industry is divided into therapy type, route of administration, distribution channel, and region.

The market segments by therapy type include chemotherapy, immunotherapy, targeted therapy, and others. In 2023, the immunotherapy segment led the market, accounting for USD 972.7 million. Immunotherapy emerges as a beacon of hope for head and neck cancer patients, especially those grappling with advanced or recurrent stages. By harnessing the body's immune system to identify and combat cancer cells, immunotherapy presents a compelling alternative to conventional treatments, such as surgery, radiation, and chemotherapy.

Routes of administration for head and neck cancer therapeutics include injectables, oral methods, and others. The injectables commanded a dominant 57.4% share in 2023. Leading immunotherapy agents for head and neck cancer, including Pembrolizumab (Keytruda) and Nivolumab (Opdivo), are primarily delivered via IV injectables. These agents target specific proteins on cancer or immune cells, necessitating direct bloodstream administration for optimal efficacy.

North America led the global head and neck cancer therapeutics market, generated USD 661.4 million in revenue in 2023 with projections to hit USD 1.4 billion by 2032. This regional leadership is attributed to a robust healthcare infrastructure and regulatory frameworks that fast-track the introduction and acceptance of innovative therapies. Furthermore, increased patient awareness coupled with access to cutting-edge treatment options cements North America's position in the industry landscape.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of head and neck cancer
    • 3.2.1.2 Growing geriatric population base
    • 3.2.1.3 Rising investment in R&D to develop new drugs
    • 3.2.1.4 Supportive reimbursement policies and rising awareness about disease
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Side effects and safety concerns
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Therapy Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Chemotherapy
• 5.3 Immunotherapy
• 5.4 Targeted therapy
• 5.5 Other therapies

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Injectable
• 6.3 Oral
• 6.4 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacy
• 7.3 Retail and specialty pharmacy
• 7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AbbVie Inc.
• 9.2 Amgen Inc.
• 9.3 AstraZeneca plc
• 9.4 Bristol-Myers Squibb Company (BMS)
• 9.5 C.H. Boehringer Sohn AG and Co. KG
• 9.6 Clinigen Group plc.
• 9.7 Coherus BioSciences
• 9.8 Cumberland Pharmaceuticals, Inc.
• 9.9 Eli Lilly and Company
• 9.10 F. Hoffmann-La Roche Ltd.
• 9.11 GSK plc
• 9.12 Merck and Co., Inc.
• 9.13 Sanofi S.A.
• 9.14 Takeda Pharmaceutical Company Limited
• 9.15 Teva Pharmaceutical Industries Ltd.